Nuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of Directors
08 Gennaio 2024 - 10:10PM
Business Wire
Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company
tackling some of the greatest unmet needs in oncology by developing
differentiated and novel therapeutic candidates, today announced
the appointment of Robert Mashal, M.D. to its Board of
Directors.
“We are delighted to have Dr. Mashal join our Board of
Directors,” said David Hung, M.D., Founder, President, and Chief
Executive Officer of Nuvation Bio. “Robert is a seasoned biotech
industry veteran and his experience as an investor, operator, and
medical oncologist will provide us with valuable insights. We look
forward to working with Robert to advance Nuvation’s pipeline.”
“Nuvation Bio is at the forefront of developing therapeutic
candidates to treat the unmet need in oncology, highlighted by the
company’s novel drug-drug conjugate platform,” said Robert Mashal,
M.D. “I am excited to leverage my past experiences to help the
Board and management bring innovative oncology therapeutics to
patients.”
Robert currently serves as a consultant to the life sciences
industry. Previously, he was the Global Head of Strategy for the
Immunology and Oncology franchises at Sanofi. Robert has worked as
CEO of NKT Therapeutics and Alinea Pharmaceuticals, two venture
capital backed life sciences firms. He was a partner at Boston
Millennia Partners, a private equity firm, where he was on the
Board of Directors of Glycofi, Cardiomems, and Sapphire
Therapeutics. He served as a Program Executive at Vertex
Pharmaceuticals, where he was on the Joint Steering Committee for
the Vertex-Novartis kinase collaboration. He was also a consultant
at McKinsey and Company. Prior to McKinsey, Dr. Mashal was a
board-certified medical oncologist and received his training in
internal medicine at the University of California, San Francisco,
and in oncology at the Dana-Farber Cancer Institute. Dr. Mashal
received his B.A. and M.D. degrees from Johns Hopkins
University.
About Nuvation Bio
Nuvation Bio is a biopharmaceutical company tackling some of the
greatest unmet needs in oncology by developing differentiated and
novel therapeutic candidates. Nuvation Bio’s proprietary portfolio
includes mechanistically distinct oncology therapeutic product
candidates, each targeting some of the most difficult-to-treat
types of cancer. Nuvation Bio was founded in 2018 by biopharma
industry veteran David Hung, M.D., who previously founded
Medivation, Inc., which brought to patients one of the world’s
leading prostate cancer medicines. Nuvation Bio has offices in New
York and San Francisco. For more information, please visit
www.nuvationbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240108092018/en/
Nuvation Bio Investor Contact: ir@nuvationbio.com
Nuvation Bio Media Contact:
nuvation@argotpartners.com
Grafico Azioni Panacea Acquisition (NYSE:NUVB)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Panacea Acquisition (NYSE:NUVB)
Storico
Da Set 2023 a Set 2024